论文部分内容阅读
CS-807是一种新研制成的口服头孢菌素,本品口服后能迅速吸收,经肠管壁的非特异性酯酶水解后,转化成有抗菌活性的R-3763而发挥治疗作用。为了客观地评价本剂对慢性呼吸道感染症的有效性、安全性等,作者以头孢克罗(以下简称CCL)为对照药,采用双盲法进行了对照试验,其结果如下: 1.199例投与本剂后,被试验委员会采用可以评价的有170例(CS-807组84例,CCL组86例)。病例按感染程度分为中等和轻症时CCL组以中等症状病例明显占多数。
CS-807 is a newly developed oral cephalosporin, oral absorption of this product can be quickly absorbed by the intestine wall non-specific esterase hydrolysis into anti-bacterial activity of R-3763 and play a therapeutic role. In order to objectively evaluate the effectiveness and safety of the agent in the treatment of chronic respiratory infections, the authors used cefaclor (hereinafter referred to as CCL) as a reference drug and conducted a double-blind control test. The results were as follows: 1.199 After treatment, 170 cases were evaluated by the test panel (84 in the CS-807 group and 86 in the CCL group). Cases were divided into moderate and mild degree of infection CCL group accounted for a clear majority of cases with moderate symptoms.